2024 net product sales of approximately $336 million exceeds upper end of guidance range; preliminary and unaudited estimate
- 2025 expected global net product sales of $420 million to $435 million
- VISTAS study of volixibat in primary sclerosing cholangitis expected to complete enrollment in second half 2025; topline data expected 2026
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.